{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:33:58Z","timestamp":1790724838050,"version":"4.1.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"Importance<\/jats:title>Patients with acute myeloid leukemia (AML) recognize days spent at home (home time) vs in a hospital or nursing facility as an important factor in treatment decision making. No study has adequately described home time among older adults with AML.<\/jats:p><\/jats:sec>Objective<\/jats:title>To describe home time among older adults with AML (aged \u226566 years) and compare home time between 2 common treatments: anthracycline-based chemotherapy and hypomethylating agents (HMAs).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>A cohort of adults aged 66 years or older with a new diagnosis of AML from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database in 2004 to 2016 was identified. Individuals were stratified into anthracycline-based therapy, HMAs, or chemotherapy, not otherwise specified (NOS) using claims.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was home time, quantified by subtracting the total number of person-days spent in hospitals and nursing facilities from the number of person-days survived and dividing by total person-days. A weighted multinomial regression model with stabilized inverse probability of treatment weighting to estimate adjusted home time was used.<\/jats:p><\/jats:sec>Results<\/jats:title>The cohort included 7946 patients with AML: 2824 (35.5%) received anthracyclines, 2542 (32.0%) HMAs, and 2580 (32.5%) were classified as chemotherapy, NOS. Median (IQR) survival was 11.0 (5.0-27.0) months for those receiving anthracyclines and 8.0 (3.0-17.0) months for those receiving HMAs. Adjusted home time for all patients in the first year was 52.4%. Home time was highest among patients receiving HMAs (60.8%) followed by those receiving anthracyclines (51.9%). Despite having a shorter median survival, patients receiving HMAs had more total days at home and 33 more days at home in the first year on average than patients receiving anthracyclines (222 vs 189).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This retrospective study of older adults with AML using SEER-Medicare data and propensity score weighting suggests that the additional survival afforded by receiving anthracycline-based therapy was entirely offset by admission to the hospital or to nursing facilities.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.1823","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:04:03Z","timestamp":1718291043000},"page":"1038","source":"Crossref","is-referenced-by-count":12,"title":["Home Time Among Older Adults With Acute Myeloid Leukemia Following Chemotherapy"],"prefix":"10.1001","volume":"10","author":[{"given":"Daniel R.","family":"Richardson","sequence":"first","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Reeder-Hayes","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Jensen","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill"},{"name":"Cecil B. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Islam","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah Poh","family":"Loh","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Gupta","sequence":"additional","affiliation":[{"name":"University of Minnesota Masonic Cancer Center, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia V.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"University of North Carolina Department of Health Policy and Management, Gillings School of Global Public Health, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F. P.","family":"Bridges","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"University of North Carolina Department of Health Policy and Management, Gillings School of Global Public Health, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wood","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Baggett","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"University of North Carolina Department of Epidemiology, Gillings School of Global Public Health, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Lund","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"University of North Carolina Department of Epidemiology, Gillings School of Global Public Health, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"coi240021r1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia.","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"coi240021r3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11899-015-0257-2","article-title":"Elderly acute myeloid leukemia: assessing risk.","volume":"10","author":"Klepin","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"issue":"24","key":"coi240021r5","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received.","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi240021r6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13187-010-0121-y","article-title":"Patient-centered communication in cancer care: the role of the NCI\u2019s Cancer Information Service.","volume":"26","author":"Perocchia","year":"2011","journal-title":"J Cancer Educ"},{"issue":"2","key":"coi240021r7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs.","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"coi240021r8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/01.mlr.0000255248.79308.41","article-title":"Are regional variations in end-of-life care intensity explained by patient preferences?: a study of the US Medicare Population.","volume":"45","author":"Barnato","year":"2007","journal-title":"Med Care"},{"issue":"4","key":"coi240021r9","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1200\/JOP.18.00338","article-title":"Days at home in the last 6 months of life: a patient-determined quality indicator for cancer care.","volume":"15","author":"Andersen","year":"2019","journal-title":"J Oncol Pract"},{"issue":"1","key":"coi240021r10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/10428194.2019.1654095","article-title":"Days spent at home in the last 6 months of life: a quality indicator of end of life care in patients with hematologic malignancies.","volume":"61","author":"Cheung","year":"2020","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"coi240021r11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/jgs.2019.67.issue-2","article-title":"Home time as a patient-centered outcome in administrative claims data.","volume":"67","author":"Lee","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"coi240021r12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1158\/1055-9965.EPI-19-1277","article-title":"Age at diagnosis and patient preferences for treatment outcomes in AML: a discrete choice experiment to explore meaningful benefits.","volume":"29","author":"Richardson","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"coi240021r13","first-page":"1006","article-title":"Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.","volume":"108","author":"Jensen","year":"2023","journal-title":"Haematologica"},{"key":"coi240021r14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284133","article-title":"Home time among older adults with acute myeloid leukemia by therapy intensity.","author":"Jensen","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"coi240021r15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/STROKEAHA.110.601302","article-title":"Home time is extended in patients with ischemic stroke who receive thrombolytic therapy: a validation study of home time as an outcome measure.","volume":"42","author":"Mishra","year":"2011","journal-title":"Stroke"},{"issue":"19","key":"coi240021r16","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1212\/WNL.0000000000004631","article-title":"Population-based study of home-time by stroke type and correlation with modified Rankin score.","volume":"89","author":"Yu","year":"2017","journal-title":"Neurology"},{"issue":"10","key":"coi240021r17","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1161\/STROKEAHA.116.013563","article-title":"Hospital variation in home-time after acute ischemic stroke: insights from the PROSPER study (patient-centered research into outcomes stroke patients prefer and effectiveness research).","volume":"47","author":"O\u2019Brien","year":"2016","journal-title":"Stroke"},{"issue":"3","key":"coi240021r18","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1161\/STROKEAHA.115.011599","article-title":"Assessment of home-time after acute ischemic stroke in Medicare beneficiaries.","volume":"47","author":"Fonarow","year":"2016","journal-title":"Stroke"},{"issue":"5","key":"coi240021r19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/eurjhf\/hfq027","article-title":"Understanding changing patterns of survival and hospitalization for heart failure over two decades in New Zealand: utility of \u2018days alive and out of hospital\u2019 from epidemiological data.","volume":"12","author":"Wasywich","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"coi240021r20","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.jacc.2018.03.517","article-title":"Home-time after discharge among patients hospitalized with heart failure.","volume":"71","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"coi240021r21","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ahj.2011.08.003","article-title":"Days alive and out of hospital and the patient journey in patients with heart failure: insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.","volume":"162","author":"Ariti","year":"2011","journal-title":"Am Heart J"},{"issue":"8","key":"coi240021r22","doi-asserted-by":"publisher","first-page":"IV-3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"issue":"7","key":"coi240021r23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"coi240021r24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pds.v24.1","article-title":"Using claims data to predict dependency in activities of daily living as a proxy for frailty.","volume":"24","author":"Faurot","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"coi240021r25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/EDE.0000000000000833","article-title":"Controlling for frailty in pharmacoepidemiologic studies of older adults: validation of an existing Medicare claims-based algorithm.","volume":"29","author":"Cuthbertson","year":"2018","journal-title":"Epidemiology"},{"issue":"25","key":"coi240021r26","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.v28:25","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"22","key":"coi240021r27","doi-asserted-by":"publisher","first-page":"8423","DOI":"10.1002\/cam4.v9.22","article-title":"Health care-related time costs in patients with metastatic breast cancer.","volume":"9","author":"Rocque","year":"2020","journal-title":"Cancer Med"},{"issue":"8","key":"coi240021r28","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1200\/JOP.19.00328","article-title":"Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma.","volume":"16","author":"Bange","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"14","key":"coi240021r29","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1002\/cncr.32074","article-title":"Willingness to bear adversity and beliefs about the curability of advanced cancer in older adults.","volume":"125","author":"Loh","year":"2019","journal-title":"Cancer"},{"key":"coi240021r30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v130.17","article-title":"Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial.","author":"Soto-Perez-de-Celis","year":"2024","journal-title":"Cancer"},{"issue":"5","key":"coi240021r31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood"},{"issue":"7","key":"coi240021r32","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/pon.v30.7","article-title":"Prioritizing the worries of AML patients: quantifying patient experience using best-worst scaling.","volume":"30","author":"Richardson","year":"2021","journal-title":"Psychooncology"},{"issue":"4","key":"coi240021r33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1200\/OP.21.00311","article-title":"Opportunity costs of surgical resection and perioperative chemotherapy for locoregional pancreatic adenocarcinoma.","volume":"18","author":"Lim","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"coi240021r34","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/MLR.0000000000000151","article-title":"Annual patient time costs associated with medical care among cancer survivors in the United States.","volume":"52","author":"Yabroff","year":"2014","journal-title":"Med Care"},{"issue":"11","key":"coi240021r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2020.3754","article-title":"Patient-centered time-at-home outcomes in older adults after surgical cancer treatment.","volume":"155","author":"Chesney","year":"2020","journal-title":"JAMA Surg"},{"issue":"3","key":"coi240021r36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/jgs.v68.3","article-title":"Time spent away from home in the year following high-risk cancer surgery in older adults.","volume":"68","author":"Suskind","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"coi240021r38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1200\/JCO.2017.74.7907","article-title":"The toxicity of time.","volume":"36","author":"Daily","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi240021r39","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1001\/jamaoncol.2021.3600","article-title":"Has the current oncology value paradigm forgotten patients\u2019 time?: too little of a good thing.","volume":"7","author":"Fundytus","year":"2021","journal-title":"JAMA Oncol"},{"issue":"15","key":"coi240021r40","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment.","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi240021r41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.beha.2018.09.005","article-title":"Is the overall survival for older adults with AML finally improving?","volume":"31","author":"Lancet","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"coi240021r42","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia.","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"coi240021r4","doi-asserted-by":"crossref","DOI":"10.17226\/18359","volume-title":"Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis","author":"Levit","year":"2013"},{"key":"coi240021r2","unstructured":"Acute Myeloid Leukemia - Cancer Stat Facts. Acute Myeloid Leukemia Statistics. Published June 18, 2019. Accessed November 18, 2018. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"coi240021r37","unstructured":"\u201cTime Spent at Home\u201d - A Patient-Defined Outcome. NEJM Catalyst. Published April 26, 2016. Accessed February 4, 2019. https:\/\/catalyst.nejm.org\/time-spent-at-home-a-patient-defined-outcome\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2820081\/jamaoncology_richardson_2024_oi_240021_1723659885.10056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:02:31Z","timestamp":1723734151000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2820081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.1823","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}